vs

Side-by-side financial comparison of Dolphin Entertainment, Inc. (DLPN) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Dolphin Entertainment, Inc. is the larger business by last-quarter revenue ($15.6M vs $12.5M, roughly 1.3× Avidity Biosciences, Inc.). Dolphin Entertainment, Inc. runs the higher net margin — 6.5% vs -1398.3%, a 1404.9% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 27.0%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 1.3%).

Dolphin Entertainment, Inc. is an American entertainment marketing and production company based in Coral Gables, Florida. Founded in 1996 by Bill O'Dowd, the company produces television series and films aimed primarily at children and young adults, and owns public relations and marketing firms through acquisitions. Dolphin has also expanded into digital media, including non-fungible token (NFT) ventures and influencer marketing.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

DLPN vs RNA — Head-to-Head

Bigger by revenue
DLPN
DLPN
1.3× larger
DLPN
$15.6M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+407.0% gap
RNA
434.0%
27.0%
DLPN
Higher net margin
DLPN
DLPN
1404.9% more per $
DLPN
6.5%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
1.3%
DLPN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
DLPN
DLPN
RNA
RNA
Revenue
$15.6M
$12.5M
Net Profit
$1.0M
$-174.4M
Gross Margin
96.6%
Operating Margin
9.5%
-1513.5%
Net Margin
6.5%
-1398.3%
Revenue YoY
27.0%
434.0%
Net Profit YoY
152.0%
-117.0%
EPS (diluted)
$0.10
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DLPN
DLPN
RNA
RNA
Q4 25
$15.6M
Q3 25
$14.8M
$12.5M
Q2 25
$14.1M
$3.8M
Q1 25
$12.2M
$1.6M
Q4 24
$12.3M
$3.0M
Q3 24
$12.7M
$2.3M
Q2 24
$11.4M
$2.0M
Q1 24
$15.2M
$3.5M
Net Profit
DLPN
DLPN
RNA
RNA
Q4 25
$1.0M
Q3 25
$-365.5K
$-174.4M
Q2 25
$-1.4M
$-157.3M
Q1 25
$-2.3M
$-115.8M
Q4 24
$-2.0M
$-102.3M
Q3 24
$-8.7M
$-80.4M
Q2 24
$-1.6M
$-70.8M
Q1 24
$-326.8K
$-68.9M
Gross Margin
DLPN
DLPN
RNA
RNA
Q4 25
96.6%
Q3 25
95.6%
Q2 25
94.7%
Q1 25
97.2%
Q4 24
96.1%
Q3 24
98.0%
Q2 24
98.1%
Q1 24
84.8%
Operating Margin
DLPN
DLPN
RNA
RNA
Q4 25
9.5%
Q3 25
2.1%
-1513.5%
Q2 25
-0.4%
-4448.7%
Q1 25
-14.6%
-8360.9%
Q4 24
-11.2%
-4069.6%
Q3 24
-64.3%
-4200.9%
Q2 24
-9.8%
-4040.4%
Q1 24
1.1%
-2178.6%
Net Margin
DLPN
DLPN
RNA
RNA
Q4 25
6.5%
Q3 25
-2.5%
-1398.3%
Q2 25
-10.0%
-4089.3%
Q1 25
-19.1%
-7360.0%
Q4 24
-15.9%
-3439.5%
Q3 24
-68.5%
-3441.7%
Q2 24
-14.2%
-3461.8%
Q1 24
-2.1%
-1943.4%
EPS (diluted)
DLPN
DLPN
RNA
RNA
Q4 25
$0.10
Q3 25
$-0.03
$-1.27
Q2 25
$-0.13
$-1.21
Q1 25
$-0.21
$-0.90
Q4 24
$-0.21
$-0.80
Q3 24
$-0.80
$-0.65
Q2 24
$-0.17
$-0.65
Q1 24
$-0.04
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DLPN
DLPN
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$8.8M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$9.7M
$1.9B
Total Assets
$58.3M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DLPN
DLPN
RNA
RNA
Q4 25
$8.8M
Q3 25
$7.8M
$350.2M
Q2 25
$8.7M
$243.9M
Q1 25
$7.1M
$254.2M
Q4 24
$8.2M
$219.9M
Q3 24
$5.7M
$370.2M
Q2 24
$8.7M
$575.8M
Q1 24
$6.4M
$471.4M
Stockholders' Equity
DLPN
DLPN
RNA
RNA
Q4 25
$9.7M
Q3 25
$8.4M
$1.9B
Q2 25
$7.9M
$1.2B
Q1 25
$9.3M
$1.3B
Q4 24
$11.6M
$1.4B
Q3 24
$13.6M
$1.5B
Q2 24
$20.4M
$1.2B
Q1 24
$20.3M
$830.9M
Total Assets
DLPN
DLPN
RNA
RNA
Q4 25
$58.3M
Q3 25
$60.0M
$2.1B
Q2 25
$58.6M
$1.4B
Q1 25
$58.6M
$1.5B
Q4 24
$58.4M
$1.6B
Q3 24
$57.3M
$1.6B
Q2 24
$65.6M
$1.3B
Q1 24
$65.1M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DLPN
DLPN
RNA
RNA
Operating Cash FlowLast quarter
$576.6K
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
0.0%
5.7%
Cash ConversionOCF / Net Profit
0.57×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DLPN
DLPN
RNA
RNA
Q4 25
$576.6K
Q3 25
$-2.4M
$-156.2M
Q2 25
$1.5M
$-199.7M
Q1 25
$-1.7M
$-124.8M
Q4 24
$850.2K
$-99.9M
Q3 24
$-1.7M
$-65.6M
Q2 24
$1.8M
$-65.0M
Q1 24
$-1.2M
$-70.4M
Free Cash Flow
DLPN
DLPN
RNA
RNA
Q4 25
Q3 25
$-2.4M
$-156.9M
Q2 25
$-203.0M
Q1 25
$-1.7M
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
DLPN
DLPN
RNA
RNA
Q4 25
Q3 25
-16.3%
-1257.6%
Q2 25
-5277.1%
Q1 25
-14.0%
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
DLPN
DLPN
RNA
RNA
Q4 25
0.0%
Q3 25
0.0%
5.7%
Q2 25
0.0%
86.9%
Q1 25
0.0%
238.6%
Q4 24
131.7%
Q3 24
0.0%
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
DLPN
DLPN
RNA
RNA
Q4 25
0.57×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons